Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Liabilities: 2016-2024

Historic Total Liabilities for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $269.9 million.

  • Akebia Therapeutics' Total Liabilities rose 25.24% to $322.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $322.6 million, marking a year-over-year increase of 25.24%. This contributed to the annual value of $269.9 million for FY2024, which is 0.89% down from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Total Liabilities is $269.9 million, which was down 0.89% from $272.3 million recorded in FY2023.
  • Akebia Therapeutics' 5-year Total Liabilities high stood at $455.3 million for FY2021, and its period low was $269.9 million during FY2024.
  • Its 3-year average for Total Liabilities is $297.7 million, with a median of $272.3 million in 2023.
  • In the last 5 years, Akebia Therapeutics' Total Liabilities rose by 14.83% in 2021 and then fell by 22.95% in 2022.
  • Akebia Therapeutics' Total Liabilities (Yearly) stood at $396.5 million in 2020, then rose by 14.83% to $455.3 million in 2021, then dropped by 22.95% to $350.8 million in 2022, then dropped by 22.39% to $272.3 million in 2023, then dropped by 0.89% to $269.9 million in 2024.